The role of miRNAs as biomarkers in prostate cancer
Introduction
Prostate cancer (PCa) is the second most common cancer among men, with a rate of 1.1 million of new cases diagnosed in 2012 [1]. There are several clinical criteria used as screening or stratification parameters such as prostate specific antigen (PSA) value, imaging diagnostics and histopathological scores (e.g. Gleason score), however these ones are not efficient as prognosis biomarkers. Currently there are some prognostic commercial biomarkers, such as Oncotype DX genomic prostate score® (Genomic health, CA, USA), Prolaris® (Myriad Genetics Inc., UT, USA), ProMark® (Metamark, MA, USA), ExoDx™ Prostate (IntelliScore, MA, USA) or Decipher® (GenomeDX, Vancouver, Canada), among others, all based on several SNPs panels or epigenetic modifications; but none of them show accurate data [2]. Some molecular biomarkers are in use, such as prostate cancer gene 3 (PCA3 or DD3) detected in urine and based on specific PCa tissue non-coding RNA, and which is currently included in the European Association of Urology (EAU) guidelines as a factor for biopsy decision making. TMPRSS2:ERG fusion transcripts are also reported as urine biomarkers that seems to be indicative of PCa aggressiveness upon biopsy. Mainly PCA3 but also TMPRSS2:ERG are considered with a valuable potential in PSA quandary situations. It is also suggested that the combination of PCA3 with TMPRSS2:ERG fusion transcripts could improve the specificity and sensitivity compared to the single use of these both non-invasive markers [3].
The main aim of current medicine is to develop efficient and non-invasive biomarkers. Most of promising PCa biomarkers are developed in urine, such as ExoDx™ Prostate (Intelliscore, MA, USA) which uses exosomal RNA for reducing the rate of unnecessary biopsies [4]; or previous described PCA3 and TMPRSS2:ERG. But it is true that there are also a high proportion of biomarkers used in tissue such as Oncotype DX genomic prostate score® (Genomic health, CA, USA), Prolaris® (Myriad Genetics Inc., UT, USA), and ProMark® (Metamark, MA, USA); used for monitoring the aggressiveness of the tumor. Moreover Decipher® (GenomeDX, Vancouver, Canada) is also detected in tissue sample but mainly focused in monitoring treatment course after prostate surgery. See more details in Supplementary Table 1.
Concerning miRNAs, miRview™mets (Rosetta Genomics, PA, USA) was the first miRNA-based cancer diagnostic available test. This test studies a 48-panel of miRNAs in tissue for 22 tumor types to determine the origin of metastasis. A second-generation test (miRview mets2), increases the number of tumor types to 49 based in a 64 miRNAs panel [5]. However, up to now there is any test based on miRNAs for the diagnosis or prognosis of primary PCa.
The development of advanced high-throughput ‘omics’ technologies has enabled the use of novel and more efficient markers guiding the prognosis and improving PCa treatment´s strategies. Currently, there are numerous molecular markers used with this aim, mainly focused on the mechanisms of castration resistance, trying to offer the best treatment opportunities. The main molecular markers are focused on: i) androgen receptor (AR) mutations, overexpression, or splice variants; ii) CYP17 variants; or iii) PARP (Poly (ADP-ribose) Polymerases) inhibitors which are the molecular targets of several treatments such as bicalutamide, flutamide, enzalutamide, abiraterone, docetaxel or cabazitaxel [6].
Among future predictive biomarkers those ones based on liquid biopsy components such as circulating tumor cells (CTCs) or free nucleic acids should also be mentioned. Here, we are focusing on the role of miRNAs, mainly in their use as cancer biomarkers. It is well known the role of miRNAs modulating important cellular cancer processes/pathways and their stability in body fluids; they are points that make these molecules as promising biomarkers.
Moreover, there are data suggesting their diagnostic (miR-21and miR-141) [7] and prognosis role (miR-141 and miR-375) in PCa [8]. All previous mentioned miRNAs characteristics suggest that these biomolecules could improve the current limitations existing in commercial panels; mainly due to their broad molecular activities and their non-invasiveness option of study. The goal of the present review is to determine the most important roles and limitations of miRNAs as biomarkers for PCa in current medicine.
Section snippets
MiRNAs
MicroRNAs (miRNAs) are small single-stranded non-coding RNAs of 18–25 nucleotides in length. These molecules regulate the expression of more than 30% of human genes by binding to the 3′-untranslated regions (3′-UTR) of specific mRNAs [9].
They are secreted by cells in different body fluids such as blood, urine, tears, saliva, breast milk and seminal fluid, etc. In the body fluids, miRNAs are protected to enzymatic degradation by their union with Argonaute2 protein and with high density
Exosomes
Exosomes are small nano-sized (30–100 nm) extracellular vesicles (EVs) secreted by almost all cells in the human body. They are present in diverse body fluids, including blood [103], urine [104], semen [105], saliva [106], among others. Due to their endosomal origin these vesicles carry proteins, lipids, and nucleic acids (including DNA and miRNAs) [107,108].
The main benefits of studying exosome-derived miRNAs are: (i) the encapsulation of miRNAs in exosomes stabilize them in body fluids,
Methodologies for detection
Several methods can be used for miRNAs´ characterization, being the most common one, the real-time PCR (qPCR), which is usually used for monitoring individual miRNAs levels. To study the whole miRNAs set NGS technologies (miRNA profile by next generation sequencing) have grown achieving improved miRNAs profiles by the use of microarrays. There are several problems for selecting miRNAs as new and efficient biomarkers in PCa. First of all, microarrays detection, digital PCR (dPCR) or qPCR are
Conclusions
In PCa, most of the conclusive biomarkers are still being invasive with procedures involving pain and other controversial clinical adverse effects. Nowadays we are closer for approaching to precision medicine and to it is routinely use in clinical practice. This disease treatment and prevention approach takes into account each person´s variability; including genomic data of each single patient. Moreover, another objective of current medicine is providing effective and non-invasive methodologies
Funding/support and role of the sponsor
We want to thank the Spanish Government for funding Alba Rodriguez Martínez (FPU14/05461).
Conflicts of interest
The authors declare that they have no conflicts of interest with the contents.
References (141)
- et al.
Biomarkers in prostate cancer – current clinical utility and future perspectives
Crit. Rev. Oncol. Hematol.
(2017) - et al.
Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review
Clin. Genitourin. Cancer
(2016) - et al.
Dysregulation of microRNAs in autoimmune diseases: pathogenesis, biomarkers and potential therapeutic targets
Cancer Lett.
(2018) - et al.
Time-course analysis of microRNA-induced mesenchymal-to-epithelial transition underscores the complexity of the underlying molecular processes
Cancer Lett.
(2018) - et al.
miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study
Asian Pac. J. Trop. Med.
(2017) - et al.
Cancer stem cells: regulation programs, immunological properties and immunotherapy
Semin. Cancer Biol.
(2018) - et al.
MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells
J. Biol. Chem.
(2012) - et al.
The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1
J. Exp. Clin. Cancer Res.: CR
(2018) - et al.
Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway
Biochem. Biophys. Res. Commun.
(2016) - et al.
MiR-185 attenuates androgen receptor function in prostate cancer indirectly by targeting bromodomain containing 8 isoform 2, an androgen receptor co-activator
Mol. Cell. Endocrinol.
(2016)
miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1
J. Biol. Chem.
miR-1207-3p is a novel prognostic biomarker of prostate cancer
Transl. Oncol.
MiR-1, a potential predictive biomarker for recurrence in prostate cancer after radical prostatectomy
Am. J. Med. Sci.
Urinary biomarkers in prostate cancer detection and monitoring progression
Crit. Rev. Oncol. Hematol.
Prostate biopsy: indications and technique
J. Urol.
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012
Int. J. Cancer
A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy
JAMA Oncol.
A second-generation microRNA-based assay for diagnosing tumor tissue origin
Oncologist
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
Ther. Adv. Med. Oncol.
Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition
Int. Urol. Nephrol.
Circulating miRNAs are correlated with tumor progression in prostate cancer
Int. J. Cancer
A five-microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data
Sci. Rep.
Cell-free microRNAs in blood and other body fluids, as cancer biomarkers
Cell Prolif.
A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy
Sci. Rep.
MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons
Int. J. Mol. Sci.
Treating cancer with microRNA replacement therapy: a literature review
J. Cell. Physiol.
miRNAs as novel biomarkers in the management of prostate cancer
Clin. Chem. Lab. Med. (CCLM)
Androgens and androgen receptor signaling in prostate tumorigenesis
J. Mol. Endocrinol.
Implications of microRNA dysregulation in the development of prostate cancer
Reproduction
Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer
Oncogene
IL-6 inhibits the targeted modulation of PDCD4 by miR-21 in prostate cancer
PLoS One
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
Nat. Med.
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
Int. J. Cancer
The MicroRNA profile of prostate carcinoma obtained by deep sequencing
Mol. Cancer Res.
MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2
PLoS One
miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes
Prostate
The basics of epithelial–mesenchymal transition (EMT): a study from a structure, dynamics, and functional perspective
J. Cell. Physiol.
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
Nat. Cell Biol.
MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer
Int. J. Mol. Sci.
Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer
Prostate
A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer
Oncogene
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Nat. Med.
miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells
Oncol. Rep.
MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms
Oncogene
miR-24 regulates CDKN1B/p27 expression in prostate cancer
Prostate
miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells
PLoS One
miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis
Oncogene
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression
Cancer Res.
miR-34a regulates expression of the Stathmin-1 oncoprotein and prostate cancer progression
Mol. Cancer Res.
miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways
Clin. Cancer Res.
Cited by (31)
An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs
2022, Translational OncologyCitation Excerpt :The salient mitogenic growth factor for prostate gland development is the androgen receptor (AR). Proteins act as a checkpoint and inhibitors in the cell cycle, and pro-apoptotic genes are silenced by miRNA [60, 61]. Epithelial cells acquire mesenchymal cells' properties during the EMT process and then contribute to invasion and metastasis [62, 63].
Emerging digital PCR technology in precision medicine
2022, Biosensors and BioelectronicsCitation Excerpt :One of the applications developed a microfluidic chamber with micropillars, which was surface-modified with anti-CD8α antibodies to rapidly gather CD8(+) EVs, followed by ddPCR measuring mRNA as a new method for testing acute ischemic stroke (Fig. 4C) (Wijerathne et al., 2020). Likewise, quantification of exosome-derived microRNA for prostate and lung cancer identification has been performed by ddPCR (Conte et al., 2015; Cozar et al., 2019). Eduardo Reátegui and colleagues constructed a microfluidic chip with staggered herringbone structure that enhanced the binding of tumor EVs to the antibody-coated surface, and then analyzed the EVs-derived mRNA through dPCR (Reátegui et al., 2018).
Breast Heterogeneity: Obstacles to Developing Universal Biomarkers of Breast Cancer Initiation and Progression
2020, Journal of the American College of SurgeonsOncogenic and tumor-suppressive microRNAs in prostate cancer
2020, Current Opinion in Endocrine and Metabolic ResearchCitation Excerpt :However, miRs can also be identified through RNA sequencing, real-time quantitative PCR, or array expression profiling of in-house cohorts. These miRs are then studied for their biological functions, which will be the focus of this review, and utility as PCa biomarkers, which has been reviewed elsewhere [2]. The gene targets of miRs can be confirmed by different assays with varying degrees of evidence.
Recent advances and future perspectives in the therapeutics of prostate cancer
2023, Experimental Hematology and Oncology
- 1
Both authors contributed equally to this study.